# Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel

> **NCT04826484** · PHASE3 · TERMINATED · sponsor: **Johns Hopkins University** · enrollment: 104 (actual)

## Conditions studied

- Urologic Diseases
- Hypospadias
- Undescended Testes
- Chordee
- Hydrocele
- Orchiectomy

## Interventions

- **DRUG:** Exparel 133 miligrams per 10 milliliter injection
- **DRUG:** Bupivacaine Hydrochloride

## Key facts

- **NCT ID:** NCT04826484
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2023-04-26
- **Final completion:** 2023-04-26
- **Target enrollment:** 104 (ACTUAL)
- **Why stopped:** Met futility threshold at interim analysis
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826484, "Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04826484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*